Journal of Cardiovascular Magnetic Resonance (Apr 2010)

Differentiation of acute and four-week old myocardial infarct with Gd(ABE-DTTA)-enhanced CMR

  • Ruzsics Balazs,
  • Kiss Pal,
  • Suranyi Pal,
  • Simor Tamas,
  • Varga-Szemes Akos,
  • Toth Levente,
  • Kirschner Robert,
  • Toth Attila,
  • Baker Robert,
  • Brott Brigitta C,
  • Litovsky Silvio,
  • Elgavish Ada,
  • Elgavish Gabriel A

DOI
https://doi.org/10.1186/1532-429X-12-22
Journal volume & issue
Vol. 12, no. 1
p. 22

Abstract

Read online

Abstract Background Standard extracellular cardiovascular magnetic resonance (CMR) contrast agents (CA) do not provide differentiation between acute and older myocardial infarcts (MI). The purpose of this study was to develop a method for differentiation between acute and older myocardial infarct using myocardial late-enhancement (LE) CMR by a new, low molecular weight contrast agent. Dogs (n = 6) were studied in a closed-chest, reperfused, double myocardial infarct model. Myocardial infarcts were generated by occluding the Left Anterior Descending (LAD) coronary artery with an angioplasty balloon for 180 min, and four weeks later occluding the Left Circumflex (LCx) coronary artery for 180 min. LE images were obtained on day 3 and day 4 after second myocardial infarct, using Gd(DTPA) (standard extracellular contrast agent) and Gd(ABE-DTTA) (new, low molecular weight contrast agent), respectively. Triphenyltetrazolium chloride (TTC) histomorphometry validated existence and location of infarcts. Hematoxylin-eosin and Masson's trichrome staining provided histologic evaluation of infarcts. Results Gd(ABE-DTTA) or Gd(DTPA) highlighted the acute infarct, whereas the four-week old infarct was visualized by Gd(DTPA), but not by Gd(ABE-DTTA). With Gd(ABE-DTTA), the mean ± SD signal intensity enhancement (SIE) was 366 ± 166% and 24 ± 59% in the acute infarct and the four-week old infarct, respectively (P Conclusions Late enhancement CMR with separate administrations of standard extracellular contrast agent, Gd(DTPA), and the new low molecular weight contrast agent, Gd(ABE-DTTA), differentiates between acute and late subacute infarct in a reperfused, double infarct, canine model.